Skip to Content
Merck
CN
  • Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.

Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2015-04-07)
Ramya Kumareswaran, Naz Chaudary, Karolina Jaluba, Alice Meng, Jenna Sykes, Asm Borhan, Richard P Hill, Robert G Bristow
ABSTRACT

Solid tumors contain regions of chronic and cyclic hypoxia. Chronic hypoxia can downregulate RAD51 and sensitize cells to PARP inhibition. Herein, we show that RAD51 expression, cell survival and toxicity to PARP inhibition is not affected under cyclic hypoxic conditions. This suggests that PARP inhibition may be selectively toxic in tumor sub-regions associated with chronic hypoxia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Bicinchoninic acid disodium salt hydrate, Vetec, reagent grade, 98%
Sigma-Aldrich
Bicinchoninic acid disodium salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Propidium iodide solution